BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Renal Solutions Announces Addition To Board Of Directors


6/27/2006 12:15:10 PM

WARRENDALE, Pa., June 27 /PRNewswire/ -- Renal Solutions, Inc., the exclusive provider of advanced sorbent hemodialysis products and services for treatment of patients with renal failure, today announced the appointment of Donald W. Joseph to the company's Board of Directors.

Mr. Joseph joined Baxter International, Inc. in 1966 and served as Group Vice-President, Corporate Officer and CEO & President of Baxter's Global Renal Business. In this capacity, Mr. Joseph successfully led the strategic development, implementation and growth of the company to the position of global market leader of renal products and services, increasing revenues from $20M to $2.0B. Currently, Mr. Joseph is President & CEO of Sorbent Therapeutics, Inc., a company focused on solutions for patients with fluid balance deficiencies.

"Don brings a wealth of senior executive experience in the global renal arena," said Peter M. DeComo, Chairman and CEO of Renal Solutions. "We are very pleased that he will be applying his talents to the Renal Solutions Board of Directors. His successful track record with renal business growth and development makes him a valuable addition to the Board in preparation for the commercial launch of the Allient(R) Sorbent Hemodialysis System," DeComo added.

"I am delighted to assist the Renal Solutions team in making this important technology widely available to clinicians, payers and patients worldwide," Mr. Joseph stated.

The Allient System opens new treatment options to dialysis professionals and patients by virtue of its ability to provide short, standard or extended duration hemodialysis therapy using just 1 & 1/2 gallons of ordinary drinking water. Numerous clinical studies have shown that an increased cumulative dialysis dose results in better patient outcomes. The Allient System provides the increased dose advantage without the need for an independent water system or large volumes of sterile fluid. This translates into increased transportability, flexibility and ease of system use.

About Renal Solutions, Inc.

http://www.renalsolutionsinc.com

Renal Solutions, Inc. is the leader in innovative, sorbent-based hemodialysis solutions and services that maximize patient outcomes and quality of life. Renal Solutions provides the most convenient and flexible treatment options, resulting in high-quality therapy and outcomes for a virtually unlimited range of treatment environments. The Allient(R) Sorbent Hemodialysis System requires only 6 liters of tap water. This capability eliminates the need for complex technology to create purified water as is necessary with conventional dialysis technology. The Allient System is transportable and can be used anywhere conventional power and tap water can be accessed.

This press release contains forward-looking statements, which if not based on historical facts, involve risks and uncertainties. Our actual results may differ materially from the results or events stated in the forward-looking statements, including, but not limited to, certain events not within the Company's control. Events which could cause results to differ include failure to meet ongoing developmental and manufacturing timelines, changing GMP requirements, the need for additional capital requirements, risks associated with the FDA/regulatory approval process, adverse changes to reimbursement for the Company's products/services and delays with respect to market acceptance of new products/services and technologies. Other risks may be detailed from time to time but the Company does not attempt to revise or update its forward- looking statements even if future experience or changes make it evident that any projected events or results expressed or implied therein will not be realized.

Renal Solutions, Inc.

CONTACT: Media Inquiries: Jennifer Bannan, Zero to Five, LLC,+1-412-580-3675, jen@0to5.com; or Commercial Inquires: Sue Bentley,Marketing Director, Renal Solutions, Inc., +1-724-772-6900 ext. 109,Sue.bentley@renalsolutionsinc.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES